Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Front Oncol. 2022 Nov 30;12:1021632. doi: 10.3389/fonc.2022.1021632. eCollection 2022.
Front Oncol. 2022.
PMID: 36531039
Free PMC article.
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S.
Prasopporn S, et al. Among authors: kongsri k.
Front Oncol. 2023 Jan 6;12:1124912. doi: 10.3389/fonc.2022.1124912. eCollection 2022.
Front Oncol. 2023.
PMID: 36686801
Free PMC article.
Item in Clipboard
Cite
Cite